Equities

Hangzhou Alltest Biotech Co Ltd

688606:SHH

Hangzhou Alltest Biotech Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)57.71
  • Today's Change-9.46 / -14.08%
  • Shares traded461.33k
  • 1 Year change-20.38%
  • Beta0.8505
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,7883,8152,959
Total Receivables, Net159157286
Total Inventory189194384
Prepaid expenses232231
Other current assets, total2.181.998.30
Total current assets3,1614,1893,668
Property, plant & equipment, net762327248
Goodwill, net------
Intangibles, net1109328
Long term investments372254
Note receivable - long term------
Other long term assets------
Total assets4,1164,6954,008
LIABILITIES
Accounts payable78171361
Accrued expenses328343
Notes payable/short-term debt000
Current portion long-term debt/capital leases168.3220
Other current liabilities, total149249290
Total current liabilities274511714
Total long term debt7.661317
Total debt242237
Deferred income tax----3.20
Minority interest4.314.40--
Other liabilities, total2.68----
Total liabilities289529735
SHAREHOLDERS EQUITY
Common stock795454
Additional paid-in capital1,7131,7441,733
Retained earnings (accumulated deficit)2,1072,4551,487
Treasury stock - common(103)(116)--
Unrealized gain (loss)------
Other equity, total31280.26
Total equity3,8274,1663,274
Total liabilities & shareholders' equity4,1164,6954,008
Total common shares outstanding787880
Treasury shares - common primary issue1.121.530
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.